Selexys Pharmaceuticals Signs CMO Agreement with Cytovance Biologics - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Selexys Pharmaceuticals Signs CMO Agreement with Cytovance Biologics



Cytovance Biologics, a CMO of mammalian and microbial biologics, announced a development and manufacturing agreement for SELK2 with Selexys Pharmaceuticals, an Oklahoma City-based clinical stage biopharmaceutical company.

SELK2 is an investigational humanized monoclonal antibody directed toward the treatment of Crohn’s disease and multiple myeloma. Selexys has contracted Cytovance Biologics as its CMO to provide process development, scale up, and cGMP manufacturing services of SELK2 in support of a Phase I human clinical trial.

Source: Cytovance Biologics

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here